Transgenic/JJ
expression/NN
of/IN
PML/RARalpha/NN
impairs/VBZ
myelopoiesis/NN
./.

The/DT
translocation/NN
found/VBN
in/IN
acute/JJ
promyelocytic/JJ
leukemia/NN
rearranges/VBZ
the/DT
promyelocytic/JJ
leukemia/NN
gene/NN
(/(
PML/NN
)/)
on/IN
chromosome/NN
15/CD
with/IN
the/DT
retinoic/JJ
acid/NN
receptor/NN
alpha/NN
(/(
RARalpha/NN
)/)
on/IN
chromosome/NN
17/CD
./.
=====
This/DT
yields/VBZ
a/DT
fusion/NN
transcript/NN
,/,
PML/RARalpha/NN
,/,
a/DT
transcription/NN
factor/NN
with/IN
reported/VBN
dominant/JJ
negative/JJ
functions/NNS
in/IN
the/DT
absence/NN
of/IN
hormone/NN
./.
=====
Clinical/JJ
remissions/NNS
induced/VBN
with/IN
all-trans/JJ
retinoic/JJ
acid/NN
(/(
RA/NN
)/)
treatment/NN
in/IN
acute/JJ
promyelocytic/JJ
leukemia/NN
are/VBP
linked/VBN
to/TO
PML/RARalpha/NN
expression/NN
in/IN
leukemic/JJ
cells/NNS
./.
=====
To/TO
evaluate/VB
the/DT
PML/RARalpha/NN
role/NN
in/IN
myelopoiesis/PRP$
,/,
transgenic/JJ
mice/NNS
expressing/VBG
PML/RARalpha/NN
were/VBD
engineered/VBN
./.
=====
A/DT
full-length/JJ
PML/RARalpha/NN
cDNA/NN
driven/VBN
by/IN
the/DT
CD11b/NN
promoter/NN
was/VBD
expressed/VBN
in/IN
transgenic/JJ
mice/NNS
./.
=====
Expression/NN
was/VBD
confirmed/VBN
in/IN
the/DT
bone/NN
marrow/NN
with/IN
a/DT
reverse/JJ
transcription/NN
PCR/NN
assay/NN
./.
=====
Basal/JJ
total/JJ
white/JJ
blood/NN
cell/NN
and/CC
granulocyte/NN
counts/NNS
did/VBD
not/RB
appreciably/RB
differ/VB
between/IN
PML/RARalpha/NN
transgenic/JJ
and/CC
control/NN
mice/NNS
./.
=====
Cell/NN
sorter/NN
analysis/NN
of/IN
CD11b+/JJ
bone/NN
marrow/NN
cells/NNS
revealed/VBD
similar/JJ
CD11b+/JJ
populations/NNS
in/IN
transgenic/JJ
and/CC
control/NN
mice/NNS
./.
=====
However/RB
,/,
in/FW
vitro/FW
clonal/JJ
growth/NN
assays/NNS
performed/VBN
on/IN
peripheral/JJ
blood/NN
from/IN
transgenic/JJ
versus/CC
control/NN
mice/NNS
revealed/VBD
a/DT
marked/JJ
reduction/NN
of/IN
myeloid/JJ
progenitors/NNS
,/,
especially/RB
in/IN
those/DT
responding/VBG
to/TO
granulocyte/ macrophage/NN
colony-stimulating/JJ
factor/NN
./.
=====
Granulocyte/macrophage/NN
colony-stimulating/JJ
factor/NN
and/CC
kit/NN
ligand/NN
cotreatment/NN
did/VBD
not/RB
overcome/VB
this/DT
inhibition/NN
./.
=====
Impaired/JJ
myelopoiesis/NN
in/FW
vivo/FW
was/VBD
shown/VBN
by/IN
stressing/VBG
these/DT
mice/NNS
with/IN
sublethal/JJ
irradiation/NN
./.
=====
Following/VBG
irradiation/NN
,/,
PML/RARalpha/NN
transgenic/JJ
mice/NNS
,/,
as/IN
compared/VBN
with/IN
controls/NNS
,/,
more/RBR
rapidly/RB
depressed/VBD
peripheral/JJ
white/JJ
blood/NN
cell/NN
and/CC
granulocyte/NN
counts/NNS
./.
=====
As/IN
expected/VBN
,/,
nearly/RB
all/DT
control/NN
mice/NNS
(/(
94.4/CD
%/NN
)/)
survived/VBD
irradiation/NN
,/,
yet/CC
this/DT
irradiation/NN
was/VBD
lethal/JJ
to/TO
45.8/CD
%/NN
of/IN
PML/RARalpha/NN
transgenic/JJ
mice/NNS
./.
=====
Lethality/NN
was/VBD
associated/VBN
with/IN
more/RBR
severe/JJ
leukopenia/NN
in/IN
transgenic/JJ
versus/CC
control/NN
mice/NNS
./.
=====
Retinoic/JJ
acid/NN
treatment/NN
of/IN
irradiated/JJ
PML/RARalpha/NN
mice/NNS
enhanced/VBD
granulocyte/NN
recovery/NN
./.
=====
These/DT
data/NNS
suggest/VBP
that/IN
abnormal/JJ
myelopoiesis/NN
due/IN
to/TO
PML/RARalpha/NN
expression/NN
is/VBZ
an/DT
early/JJ
event/NN
in/IN
oncogenic/JJ
transformation/NN
./.